Live feed14:00:00·27dPRReleasevia QuantisnowRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancerByQuantisnow·Wall Street's wire, on your screen.JNJ· Johnson & JohnsonHealth Care
